China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (CPHI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cphi · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for China Pharma Holdings, Inc. (CPHI) measures how much investors pay for each dollar of the company's trailing earnings. CPHI's current PE ratio of N/A is calculated by dividing its stock price of $0.71 by its TTM earnings per share of -$0.83.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%298.5x
MedianQ3 · 75%609.7x
Max
At N/A, CPHI's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
China Pharma Holdings, Inc.You CPHI | $2M | N/A | — | -$0.83 |
 Autonomix Medical, Inc. Common Stock AMIX | $2M | N/A | — | -$0.23 |
 Ensysce Biosciences, Inc. ENSC | $2M | N/A | — | -$3.98 |
 Flora Growth Corp. FLGC | $4M | N/A | — | $0.00 |
 KALA BIO, Inc. KALA | $50M | N/A | — | -$3.31 |
 Oragenics, Inc. OGEN | $3M | N/A | — | -$4.56 |
 RedHill Biopharma Ltd. RDHL | $3M | N/A | — | -$0.14 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.74 | — | |
2024-12-31 FY2024 | — | $-0.27 | — | |
2023-12-31 FY2023 | — | $-0.29 | — | |
2022-12-31 FY2022 | — | $-0.76 | — | |
2021-12-31 FY2021 | — | $-0.74 | — | |
2020-12-31 FY2020 | — | $-0.62 | — | |
2019-12-31 FY2019 | — | $-4.49 | — | |
2018-12-31 FY2018 | — | $-2.33 | — | |
2017-12-31 FY2017 | — | $-4.18 | — | |
2016-12-31 FY2016 | — | $-1.99 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for China Pharma Holdings, Inc. (CPHI) measures how much investors pay for each dollar of the company's trailing earnings. CPHI's current PE ratio of N/A is calculated by dividing its stock price of $0.71 by its TTM earnings per share of -$0.83.
Frequently asked questions
CPHI pe ratio · 6 questionsCPHI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.71 and TTM EPS of -$0.83. Data sourced from Financial Modeling Prep via CPHI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · China Pharma Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08